寡转移性疾病成像策略与技术挑战:EORTC成像组建议
本文讨论寡转移性疾病(OMD)患者成像的证据与推荐。文章提出按疾病周期(诊断、疗效评估、随访)结合肿瘤类型、转移部位及既往治疗,选择标准成像(CT、MRI、骨 scintigraphy)或先进成像(功能、代谢及放射性核素靶向),以优化OMD临床试验与临床管理。
要点
- OMD成像需求随肿瘤类型、转移部位及与既往治疗的时间关系而异。
- 每个疾病周期节点成像需针对临床问题及既往治疗背景定制。
- 全身成像方法的选择需根据临床风险评估合理化。
核心结论
- OMD的成像应按疾病周期节点和临床背景定制,以支持转移导向消融治疗的临床试验和临床决策。
研究设计与样本
- 欧洲癌症研究与治疗组织(EORTC)成像组发布的建议文件,基于证据讨论并推荐OMD的标准成像和先进成像方法。
主要发现
- OMD患者症状常可控且可能治愈,手术和放疗技术进步使转移导向消融治疗成为标准系统治疗的辅助或替代选择。
- 多个临床试验和登记研究正在不同瘤种中评估这些治疗方法的获益,需要正确纳入并适当成像随访患者。
- 标准成像包括CT上的RECIST测量、MRI和骨闪烁显像;先进成像包括功能、代谢和放射性核素靶向方法。
- 全身成像方法如18F-FDG-PET/CT、弥散加权MRI、18F-Choline-PET/CT和68Ga-PSMA-PET/CT的选择需根据临床风险评估合理化。
关键数值与推荐
- 标准成像推荐:CT上RECIST测量、MRI和骨闪烁显像用于OMD患者的识别和随访。
- 先进成像推荐:功能、代谢和放射性核素靶向方法用于OMD患者的识别和随访。
- 成像需求随肿瘤类型、转移位置和相对于既往治疗的测量时机而变化。
- 在诊断、疗效评估和随访每个疾病周期节点,成像必须针对临床问题和既往治疗背景定制。
- 全身方法的选择需根据临床风险评估合理化,如18F-FDG-PET/CT、弥散加权MRI、18F-Choline-PET/CT和68Ga-PSMA-PET/CT。
临床怎么用
- 临床中应根据肿瘤类型、转移部位和既往治疗时机,在诊断、疗效评估和随访时选择并定制成像方案。
- 对OMD患者考虑转移导向消融治疗时,需使用适当成像正确纳入和随访患者。
- 全身先进成像方法的选择应基于临床风险评估进行合理化,避免不加区分使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with oligometastatic disease (OMD) often have controllable symptoms, and cures are possible. Technical improvements in surgery and radiotherapy have introduced the option of metastasis-directed ablative therapies as an adjunct or alternative to standard-of-care systemic therapies. Several clinical trials and registries are investigating the benefit of these therapeutic approaches across several cancer sites. This requires that patients are correctly included and followed with appropriate imaging. This article discusses the evidence and offers recommendations for the implementation of standard-of-care (Response Evaluation Criteria in Solid Tumours measurements on computed tomography [CT], magnetic resonance imaging [MRI] and bone scintigraphy) and advanced imaging modalities (functional, metabolic and radionuclide targeted) for identifying and following up patients with OMD. Imaging requirements for recognising OMD vary with tumour type, metastatic location, and timing of measurement in relation to previous treatment. At each point in the disease cycle (diagnosis, response assessment and follow-up), imaging must be tailored to the clinical question and the context of prior treatment. The differential use of whole-body approaches such as 18F-FDG-positron emission tomography (PET)/CT, diffusion-weighted MRI, 18F-Choline-PET/CT and 68Ga-prostate specific membrane antigen-PET/CT require rationalisation depending on clinical risk assessment. Optimal standardised imaging approaches will enable OMD trials to document patterns of disease progression and outcomes of treatment. Quality assured and quality controlled imaging data included in databases such as the European Organisation for Research and Treatment of Cancer Imaging platform for the Oligocare trial (a prospective, large-scale observational basket study being set up to collect outcome data from patients with OMD treated with radiation therapy) will establish a large and high-quality imaging warehouse for future research.
引用
- deSouza NM, Liu Y, Chiti A, et al. Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer. 2018. PMID: 29331524. doi:10.1016/j.ejca.2017.12.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。